tradingkey.logo

Virax Biolabs Group Ltd

VRAX
查看詳細走勢圖
0.370USD
+0.020+5.69%
收盤 12/24, 13:00美東報價延遲15分鐘
2.42M總市值
虧損本益比TTM

Virax Biolabs Group Ltd

0.370
+0.020+5.69%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+5.69%

5天

-8.33%

1月

-2.81%

6月

-53.85%

今年開始到現在

-83.56%

1年

-78.49%

查看詳細走勢圖

TradingKey Virax Biolabs Group Ltd股票評分

單位: USD 更新時間: 2025-10-27

操作建議

當前估值合理,機構持股佔比非常高,目前股價在壓力位和支撐位之間,可以做區間波段操作。

Virax Biolabs Group Ltd評分

相關信息

行業排名
315 / 501
全市場排名
651 / 4682
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 0 分析師
--
評級
--
目標均價
--
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Virax Biolabs Group Ltd亮點

亮點風險
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
業績增長期
公司處於發展階段,最新年度總收入6.33K美元
估值高估
公司最新PE估值-0.36,處於3年歷史高位
機構減倉
最新機構持股263.20K股,環比減少16.85%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉0.00股
活躍度增加
近期活躍度增加,過去20天平均換手率0.02

Virax Biolabs Group Ltd新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Virax Biolabs Group Ltd簡介

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
公司代碼VRAX
公司Virax Biolabs Group Ltd
CEOFoster (James)
網址https://www.viraxbiolabs.com

常見問題

Virax Biolabs Group Ltd(VRAX)的當前股價是多少?

Virax Biolabs Group Ltd(VRAX)的當前股價是 0.370。

Virax Biolabs Group Ltd 的股票代碼是什麼?

Virax Biolabs Group Ltd的股票代碼是VRAX。

Virax Biolabs Group Ltd股票的52週最高點是多少?

Virax Biolabs Group Ltd股票的52週最高點是3.200。

Virax Biolabs Group Ltd股票的52週最低點是多少?

Virax Biolabs Group Ltd股票的52週最低點是0.350。

Virax Biolabs Group Ltd的市值是多少?

Virax Biolabs Group Ltd的市值是2.42M。

Virax Biolabs Group Ltd的淨利潤是多少?

Virax Biolabs Group Ltd的淨利潤為-6.06M。

現在Virax Biolabs Group Ltd(VRAX)的股票是買入、持有還是賣出?

根據分析師評級,Virax Biolabs Group Ltd(VRAX)的總體評級為--,目標價格為--。

Virax Biolabs Group Ltd(VRAX)股票的每股收益(EPS TTM)是多少

Virax Biolabs Group Ltd(VRAX)股票的每股收益(EPS TTM)是-1.625。
KeyAI